Shopping Cart 0
Cart Subtotal
USD 0

Alembic Pharmaceuticals Ltd (APLLTD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company's active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antibacterial, cardiovascular, gynecological, cough and cold, gastroenterological, ophthalmological, anti-diabetic, orthopedic, urology, antihistamine, dermatological and herbal nutraceuticals. APL provides generic formulations such as anti-allergic, anthelmintic, antimicrobials, antiulcerants, nutritional and vitamin preparations, and others speciality products. The company has its research centres and manufacturing facilities in Vadodara, Gujarat and Baddi. APL is headquartered in Vadodara, Gujarat, India.

Alembic Pharmaceuticals Ltd (APLLTD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Alembic Pharma to Form Joint Venture with Orbicular Pharma 13

TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 14

Licensing Agreements 16

Novartis Enters into Licensing Agreement with Rhizen Pharma 16

TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17

Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 19

Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 20

Debt Offering 21

Alembic Pharma to Raise up to USD41.5 Million in Private Placement of Debentures 21

Asset Transactions 22

Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 22

Acquisition 23

Alembic Pharma Acquires Orit Labs 23

Alembic Pharma to Acquire 49% Stake in Adwiya Mami 24

Alembic Pharmaceuticals Ltd-Key Competitors 25

Alembic Pharmaceuticals Ltd-Key Employees 26

Alembic Pharmaceuticals Ltd-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 29

Financial Announcements 29

Jul 20, 2017: Alembic Pharmaceuticals: QI Net Revenue at Rs 648 Crores, Net Profit at Rs 65 Crores 29

May 03, 2017: Alembic Pharmaceuticals: Q4 Net Revenue grew 18% to Rs 740 Crores, Net Profit at Rs 94 cr 31

Jan 25, 2017: Alembic Pharmaceuticals: Q3 Net Profit at Rs 86 cr, Net Revenues at Rs 776 cr 32

Legal and Regulatory 33

Jun 15, 2018: Alembic Pharmaceuticals Receives Establishment Inspection Report For Its Formulation Facility At Panelav 33

May 18, 2018: Alembic Pharmaceuticals Provides Update on US FDA Inspection At its API Facility At Karkhadi 34

Apr 24, 2018: Alembic Pharmaceuticals: Update on Successful US FDA Inspection API Facility at Panelav 35

Mar 21, 2018: USFDA Inspection Formulation Facility at Panelav 36

Aug 31, 2017: Alembic Pharmaceuticals Receives EU GMP Certificate For Its Formulation Facility At Panelav 37

Mar 10, 2017: Alembic Pharmaceuticals Announces US FDA Inspection at Baroda Facility 38

Government and Public Interest 39

Apr 17, 2017: Successful US FDA Inspection at Alembic Pharmaceuticals Bioequivalence Facility at Baroda 39

Other Significant Developments 40

Aug 18, 2017: Alembic Pharmaceuticals: Disruption in plant operations at Algerian JV 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alembic Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alembic Pharma to Form Joint Venture with Orbicular Pharma 13

TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 14

Novartis Enters into Licensing Agreement with Rhizen Pharma 16

TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17

Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 19

Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 20

Alembic Pharma to Raise up to USD41.5 Million in Private Placement of Debentures 21

Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 22

Alembic Pharma Acquires Orit Labs 23

Alembic Pharma to Acquire 49% Stake in Adwiya Mami 24

Alembic Pharmaceuticals Ltd, Key Competitors 25

Alembic Pharmaceuticals Ltd, Key Employees 26

Alembic Pharmaceuticals Ltd, Other Locations 27

Alembic Pharmaceuticals Ltd, Subsidiaries 27

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Alembic Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Alembic Pharmaceuticals Ltd (APL) is a pharmaceutical company which manufactures and markets generic pharmaceutical products. The company's active pharmaceutical ingredients include macrolides, NSAIDs, and other drugs. It also offers branded formulations in the areas of antibiotics and antibacterial, cardiovascular, gynecological, cough and cold, gastroenterological, ophthalmological, anti-diabetic, orthopedic, urology, antihistamine, dermatological and herbal nutraceuticals. APL provides generic formulations such as anti-allergic, anthelmintic, antimicrobials, antiulcerants, nutritional and vitamin preparations, and others speciality products. The company has its research centres and manufacturing facilities in Vadodara, Gujarat and Baddi. APL is headquartered in Vadodara, Gujarat, India.

Alembic Pharmaceuticals Ltd (APLLTD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Alembic Pharma to Form Joint Venture with Orbicular Pharma 13

TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 14

Licensing Agreements 16

Novartis Enters into Licensing Agreement with Rhizen Pharma 16

TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17

Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 19

Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 20

Debt Offering 21

Alembic Pharma to Raise up to USD41.5 Million in Private Placement of Debentures 21

Asset Transactions 22

Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 22

Acquisition 23

Alembic Pharma Acquires Orit Labs 23

Alembic Pharma to Acquire 49% Stake in Adwiya Mami 24

Alembic Pharmaceuticals Ltd-Key Competitors 25

Alembic Pharmaceuticals Ltd-Key Employees 26

Alembic Pharmaceuticals Ltd-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 29

Financial Announcements 29

Jul 20, 2017: Alembic Pharmaceuticals: QI Net Revenue at Rs 648 Crores, Net Profit at Rs 65 Crores 29

May 03, 2017: Alembic Pharmaceuticals: Q4 Net Revenue grew 18% to Rs 740 Crores, Net Profit at Rs 94 cr 31

Jan 25, 2017: Alembic Pharmaceuticals: Q3 Net Profit at Rs 86 cr, Net Revenues at Rs 776 cr 32

Legal and Regulatory 33

Jun 15, 2018: Alembic Pharmaceuticals Receives Establishment Inspection Report For Its Formulation Facility At Panelav 33

May 18, 2018: Alembic Pharmaceuticals Provides Update on US FDA Inspection At its API Facility At Karkhadi 34

Apr 24, 2018: Alembic Pharmaceuticals: Update on Successful US FDA Inspection API Facility at Panelav 35

Mar 21, 2018: USFDA Inspection Formulation Facility at Panelav 36

Aug 31, 2017: Alembic Pharmaceuticals Receives EU GMP Certificate For Its Formulation Facility At Panelav 37

Mar 10, 2017: Alembic Pharmaceuticals Announces US FDA Inspection at Baroda Facility 38

Government and Public Interest 39

Apr 17, 2017: Successful US FDA Inspection at Alembic Pharmaceuticals Bioequivalence Facility at Baroda 39

Other Significant Developments 40

Aug 18, 2017: Alembic Pharmaceuticals: Disruption in plant operations at Algerian JV 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Alembic Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Alembic Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Alembic Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Alembic Pharma to Form Joint Venture with Orbicular Pharma 13

TG Therapeutics Enters Into Agreement With Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 14

Novartis Enters into Licensing Agreement with Rhizen Pharma 16

TG Therapeutics Exercises Option for Licensing Agreement with Rhizen Pharma To Develop PI3K Delta Inhibitor, TGR-1202 17

Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 19

Accu-Break Pharma Enters Into Licensing Agreement With Alembic Pharma To Develop Novel Pharma Products 20

Alembic Pharma to Raise up to USD41.5 Million in Private Placement of Debentures 21

Alembic Pharma Sells its Formulations Manufacturing Facility to Scott-Edil Pharmacia 22

Alembic Pharma Acquires Orit Labs 23

Alembic Pharma to Acquire 49% Stake in Adwiya Mami 24

Alembic Pharmaceuticals Ltd, Key Competitors 25

Alembic Pharmaceuticals Ltd, Key Employees 26

Alembic Pharmaceuticals Ltd, Other Locations 27

Alembic Pharmaceuticals Ltd, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Alembic Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.